Novartis issues warning for breast cancer drug Femara

Share this article:

Novartis last week issued a warning that its breast cancer drug, Femara (letrozole), has been associated with birth defects, a caution prompted by reports that the drug was being used to help a woman become pregnant.
Femara is approved for use only in postmenopausal women with breast cancer. But there is evidence some doctors have prescribed it as a fertility treatment because it suppresses estrogen and can promote ovulation.
Novartis is sending letters to fertility doctors worldwide to reiterate a warning that the drug should not be given to women who may be pregnant, a company spokeswoman said in published reports.
The FDA has not taken any action, but a spokeswoman told the Associated Press that the agency was reviewing the matter. Novartis reportedly plans to send a letter to U.S. fertility specialists in coming days.

Share this article:

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.